Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
BMS's Opdivo scores overall survival triumph in NSCLC trial
BMS has bolstered its case for Opdivo as a preoperative treatment for NSCLC as it has delivered an overall survival edge when added to chemo.
Kevin Dunleavy
Feb 19, 2025 10:06am
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
Feb 14, 2025 8:15am
J&J's Rybrevant-Lazcluze tops AZ's Tagrisso on overall survival
Jan 7, 2025 8:00am
China-made lung cancer drug plays catch-up with Pfizer, Roche
Dec 19, 2024 10:20am
Keytruda-Lynparza combo scores tepid win in ovarian cancer trial
Dec 9, 2024 11:18am
FDA expands label for AZ's Tagrisso in NSCLC indication
Sep 26, 2024 10:52am
